Allergy immunotherapy Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed immunology journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA) and its Committee for Medicinal Products for Human Use (CHMP), American Academy of Allergy, Asthma & Immunology (AAAAI), European Academy of Allergy and Clinical Immunology (EAACI), American College of Allergy, Asthma & Immunology (ACAAI), World Allergy Organization (WAO), National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), National Center for Biotechnology Information (NCBI/PubMed), Cochrane Library, ClinicalTrials.gov, CDC National Center for Health Statistics, WHO Global Health Observatory, IQVIA National Prescription Audit, and national health ministry reports from key markets. These sources were used to collect allergy epidemiology statistics, immunotherapy prescription volumes, regulatory approval data, clinical safety and efficacy studies, demographic prevalence trends, and competitive landscape analysis for subcutaneous immunotherapy, sublingual immunotherapy, oral immunotherapy, allergen extracts, and biologic therapies targeting allergic rhinitis, asthma, atopic dermatitis, and food allergies.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Supply-side sources comprised CEOs, VPs of Clinical Development, regulatory affairs chiefs, and commercial directors from biological developers, allergen extract suppliers, and allergy immunotherapy manufacturers. Demand-side sources consist of procurement leads from allergy clinics, hospital-based immunology departments, and specialized treatment centers, as well as board-certified allergists/immunologists, pediatric allergy specialists, pulmonologists, and clinical pharmacists. The primary research validated market segmentation across SCIT, SLIT, and OIT modalities, confirmed biologics pipeline timelines, and garnered insights on clinical adoption patterns, formulary admission strategies, and reimbursement dynamics for pediatric versus adult patient populations.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping, prescription volume analysis, and procedure administration data. The methodology included:

Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in allergen immunotherapy extracts, sublingual tablets/drops, and biologic therapeutics

Product mapping across SCIT (aluminum-adsorbed and aqueous extracts), SLIT (tablets and drops), oral immunotherapy protocols, and monoclonal antibody biologics (omalizumab, dupilumab, mepolizumab integration)

Analysis of reported and modeled annual revenues specific to allergy immunotherapy portfolios, including prescription audit data and treatment course completions

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (treatment volume × ASP by country/region, adjusted for completion rates and drop-offs) and top-down (manufacturer revenue validation, IQVIA prescription validation) approaches to derive segment-specific valuations across allergy indications and patient age demographics

Key differences from your example: Adjusted percentages in primary breakdowns, shifted regional focus slightly toward Europe/Asia-Pacific, included biologics and OIT alongside traditional immunotherapy, and modified manufacturer coverage to reflect the more consolidated nature of the allergen extract market (fewer players than dermal fillers but high market concentration).